N-acetylcarnosine lubricant eyedrops possess all-in-one universal antioxidant protective effects of L-carnosine in aqueous and lipid membrane environments, aldehyde scavenging, and transglycation activities inherent to cataracts: A clinical study of the new vision-saving drug n-acetylcarnosine eyedrop therapy in a database population of over 50,500 patients

American Journal of Therapeutics

Volumn 16, Issue 6, 2009, Pages 517-533

  Babizhayev, Mark A ^a   Micans, Philip ^b   Guiotto, Andrea ^c,d   Kasus Jacobi, Anne ^e  

^a Innovative Vision Products   (United States)

^b IAS Group   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d CNR   (Italy)

^e UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Age related ophthalmic diseases; Aldehyde scavenging; Cataracts; Hydrazide carnosine derivatives; L carnosine; N acetylcarnosine lubricant eyedrops; Transglycation

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDEHYDE; ASCORBIC ACID; BENZYL ALCOHOL; CARBOXYMETHYLCELLULOSE; CARNOSINE; ETHYLAMINE; EYE DROPS; GLUCOSE; GLYCEROL; IRON; LUBRICATING AGENT; MALONALDEHYDE; N ACETYLCARNOSINE; PENETRATION ENHANCING AGENT; PLACEBO; POTASSIUM BICARBONATE; POTASSIUM BORATE; REACTIVE OXYGEN METABOLITE; SCHIFF BASE; UNCLASSIFIED DRUG;

ADULT; AGED; AGING; ANTIOXIDANT ACTIVITY; AQUEOUS SOLUTION; ARTICLE; BLINDNESS; CATARACT; CHEMICAL MODEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS LINKING; DIABETES MELLITUS; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; DRUG SYNTHESIS; FEMALE; GLYCATION; HEALTH CARE COST; HUMAN; LIPID MEMBRANE; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; MUCOADHESION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVOR; SUSTAINED RELEASE FORMULATION; VISION; VISUAL ACUITY; VISUAL IMPAIRMENT;

ADMINISTRATION, TOPICAL; AGED; AGED, 80 AND OVER; ANTIOXIDANTS; CARNOSINE; CATARACT; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LIPID PEROXIDATION; LIPOSOMES; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; OXIDATIVE STRESS; PRODRUGS; PROSPECTIVE STUDIES;

EID: 74549215049     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e318195e327     Document Type: Article

References (40)

1. Ganley JP, Roberts J, eds. Eye Conditions and Related Need for Medical Care Among Persons 1-74 Years of Age, United States, 1971-1972. Hyattsville, MD: U.S. Dept. of Health and Human Services, Public Health Service, National Center for Health Statistics; 1983 (DHHS publication no. 83-1678).
2. Shmuely-Dulitzki Y, Rovner BW. Screening for depression in older persons with low vision: somatic eye symptoms and the Geriatric Depression Scale. Am J Geriatr Psychiatry. 1997;5:216-220.
3. Babizhayev MA, Deyev AI, Yermakova VN, et al. Revival of the lens transparency with N-acetylcarnosine. Curr Drug Ther. 2006;1:91-116.
4. Babizhayev MA, Deyev AI, Yermakova VN, et al. NAcetylcarnosine, a natural histidine-containing dipeptide, as a potent ophthalmic drug in treatment of human cataracts. Peptides. 2001;22:979-994.
5. Babizhayev MA, Deyev AI, Yermakova VN, et al. Lipid peroxidation and cataracts: N-acetylcarnosine as a therapeutic tool to manage age-related cataracts in human and in canine eyes. Drugs Res Devel. 2004;5:125-139.
6. Babizhayev MA, Deyev AI. Lens opacity induced by lipid peroxidation products as a model of cataract associated with retinal disease. Biochim Biophys Acta. 1989;1004: 124-133.
7. Babizhayev MA, Deyev AI, Linberg LF. Lipid peroxidation as a possible cause of cataract. Mech Ageing Devel. 1988;44;69-89.
8. Yu T, Robotham JL, Yoon Y. Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc Natl Acad Sci USA. 2006;21:103; 2653-2658. Epub 2006 Feb 13.
9. Ansari NH, Wang L, Srivastava SK. Role of lipid aldehydes in cataractogenesis: 4-hydroxynonenal-induced cataract. Biochem Mol Med. 1996;58:25-30.
10. Guiotto A, Ruzza P, Babizhayev MA, et al. Malondialdehyde scavenging and aldose-derived Schiff bases' transglycation properties of synthetic histidyl-hydrazide carnosine analogs. Bioorganic & Medicinal Chemistry. 2007;15, 6158-6163. E-pub 2007 Jun 20.
11. Babizhayev MA. Antioxidant activity of L-carnosine, a natural histidine-containing dipeptide in crystalline lens. Biochim Biophys Acta. 1989;1004:363-371.
12. Babizhayev MA, Yermakova VN, Sakina NL, et al. Nacetylcarnosine is a prodrug of L-carnosine in ophthalmic application as antioxidant. Clinica Chimica Acta. 1996;254: 1-21.
13. Boldyrev AA, Dupin AM, Bunin AY, et al. The antioxidative properties of carnosine, a natural histidine containing dipeptide. Biochem Intl. 1987;15:1105-1113.
14. Aldini G, Carini M, Beretta G, et al. Carnosine is a quencher of 4-hydroxy-nonenal: through what mechanism of reaction? Biochem Biophys Res Commun. 2002;298: 699-706.
15. Babizhayev MA. Ophthalmic pharmacology of N-acetylcarnosine lubricant eye drops. J Pharmacol Toxicol. 2006;1: 201-233.
16. Babizhayev MA. Rejuvenation of visual functions in older adult drivers and drivers with cataract during a shortterm administration of N-acetylcarnosine lubricant eye drops. Rejuvenation Res. 2004;7:186-198.
17. Babizhayev MA, Deyev AI, Yermakova VN, et al. Efficacy of N-acetylcarnosine in the treatment of cataracts. Drugs Res Devel. 2002;3:87-103.
18. Babizhayev MA, Yermakova VN, Deyev AI, et al. Imidazole-containing peptidomimetic NACA as a potent drug for the medicinal treatment of age-related cataract in humans. J Anti-Aging Med. 2000;3:43-62.
19. Babizhayev MA. Method for topical treatment of eye disease and composition and device for said treatment. PCT patent application. International publication no. WO 2004/028536 A1. International publication date: 8 April 2004.
20. Babizhayev MA, Meguro K. Combined use of carnosinase inhibitor with L-carnosines and composition. International publication no. WO 2004/064866 PCT/JP2004/000351. Filed 20 January 2003.
21. Babizhayev MA, Bozzo Costa E. Lipid peroxide and reactive oxygen species generating systems of the crystalline lens. Biochim Biophys Acta. 1994;1225:326-337.
22. Babizhayev MA, Deyev AI, Yermakova VN, et al. Image analysis and glare sensitivity in human age-related cataracts. Clin Exp Optometry. 2003;86:157-172.
23. Babizhayev MA, Burke L, Micans P, et al. N-acetylcarnosine sustained drug delivery eye drops to control the signs of ageless vision: glare sensitivity, cataract amelioration and quality of vision. Currently available treatment for the challenging 50,000-patient population. Clinical Intervention in Aging. 2008;4:31-50.
24. Babizhayev MA, Seguin M-C. Process of assessment of ocular dysfunctions and implementation devices of this process. US Patent No. 6,007,203. Date of patent: December 28, 1999.
25. Babizhayev MA, Bozzo Costa E. Composizioni farmaceutiche contenenti N-acetilcarnosina per il trattamento della cataratta. Italian Patent A61K gruppo 37/00 20122 MI, Priority Oct. 15, 1993.
26. Babizhayev MA, Bozzo Costa E. Pharmaceutical compositions containing N-acetylcarnosine for the treatment of cataract. Patent PCT/EP 94/03340 SCB 238 PCT, Oct. 10, 1994.
27. Owsley C, Stalvey BT, Wells J, et al. Visual risk factors for crash involvement in older drivers with cataract. Arch Ophthalmol. 2001;119:881-887.
28. Kang JH, Kim KS, Choi SY, et al. Protective effects of carnosine, homocarnosine and anserine against peroxyl radical-mediated Cu, Zn-superoxide dismutase modification. Biochim Biophys Acta. 2002;1570:89-96.
29. Babizhayev MA, Seguin MC, Gueyne J, et al. L-carnosine (b-alanyl-L-histidine) and carcinine (b -alanylhistamine) act as natural antioxidants with hydroxyl-radical-scavenging and lipid peroxidase activities. Biochem J. 1994;304: 509-516.
30. Hipkiss AR, Preston JE, Himswoth DT, et al. Protective effects of carnosine against malondialdehyde-induced toxicity towards cultured rat brain endothelial cells. Neurosci Lett. 1997;238:135-138.
31. Hobart LJ, Seibel I, Yeargans GS, et al. Anti-crosslinking properties of carnosine: significance of histidine. Life Sci. 2004;75:1379-1389.
32. Hipkiss AR, Brownson C. Carnosine reacts with protein carbonyl groups: another possible role for the anti-ageing peptide? Biogerontology. 2000;1:217-223.
33. Seidler NW, Yeargans GS, Morgan TG. Carnosine disaggregates glycated alpha-crystallin: an in vitro study. Arch Biochem Biophys. 2004;427:110-115.
34. Price DI, Rhett PM, Thorpe SR, et al. Chelating activity of advanced glycation end-product inhibitors. J Biologic Chem. 2001;276:48967-48972.
35. Yamagishi S-I, Nakamura K, Imaizumi T. Advanced glycation end products (AGEs) and diabetic vascular complications. Curr Diabetes Rev. 2005;1:93-106.
36. Babizhayev MA. Glare disability and driving safety. Ophthalmic Res. 2003;35:19-25.
37. Ferris FL3rd, Kassoff A, Bresnick GH, et al. New visual acuity charts for clinical research. Am J Ophthalmol. 1982; 94:91-96.
38. Ferris FL, Sperduto RD. Standardized illumination for visual acuity testing in clinical research. Am J Ophthalmol. 1982;94:97-98.
39. Szwergold BS. Carnosine and anserine act as effective transglycating agents in decomposition of aldosederived Schiff bases. Biochem Biophys Res Commun. 2005; 336:36-41.
40. Shao L, Li QH, Tan Z. L-carosine reduces telomere damage and shortening rate in cultured normal fibroblasts. Biochem Biophys Res Commun. 2004;324:931-936.